Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
The Father Who Never Left His Son Behind
How A Silly 11-Second Song About Dr Pepper Changed Her Life Overnight
Man’s Best Friend: The Story Behind An Unforgettable Tomb In London
Senior Cat Labeled 'Sad And Scared' Finds Forever Home
She Could Have Kept Walking. Instead, She Stopped And Saved A Life
Donkey Opens Door, Then Waits Patiently To Be Let In For A Hug
Man Takes A Bull To Starbucks For A Pup Cup
His Kids Wanted To Help With His Videos, So He Let Them Narrate — It’s The Cutest Thing
'You're a Unicorn': The Dementia Caregiver Who Just Stunned The American Idol Judges
Cat Steals The Spotlight By Singing Exactly Like His Owner
